High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma
- 1 April 2016
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 44 (4) , 238-246.e2
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With PrognosisJournal of Clinical Oncology, 2015
- Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression modelsBMC Cancer, 2015
- Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP eraAnnals of Oncology, 2014
- The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with ageHaematologica, 2011
- Aggressive LymphomasNew England Journal of Medicine, 2010
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2006
- A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphomaProceedings of the National Academy of Sciences, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Genes and Mechanisms Related to RNA Interference Regulate Expression of the Small Temporal RNAs that Control C. elegans Developmental TimingCell, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000